# Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

> **NCT00338117** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 554 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia

## Interventions

- **DRUG:** Galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00338117
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-08
- **Primary completion:** —
- **Final completion:** 1997-05
- **Target enrollment:** 554 (ACTUAL)
- **Last updated:** 2010-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338117, "Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00338117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*